By alcyon|2020-12-18T18:39:26+01:00March 10th, 2021|Financial calendar|Comments Off on 2020 Fiscal Year Results
Results from Phase 1b/2 Study of TG4001 with Avelumab in Advanced HPV-Positive Cancers
https://channel.royalcast.com/webcast/transgene/20200722_1/
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster [...]
Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
AACR2020 6010 J. Foloppe et al. AACR 2020 Download the [...]
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a - Transgene PR AACR 3 posters
Combined General Meeting of May 22, 2019
20190522-TG-AGM-2019-EN